Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H19N5 |
Molecular Weight | 293.3669 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C#N)c1cc(cc(c1)C(C)(C)C#N)Cn2cncn2
InChI
InChIKey=YBBLVLTVTVSKRW-UHFFFAOYSA-N
InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
Anastrozole (marketed under the trade name Arimidex by AstraZeneca) is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens. The growth of many cancers of the breast is stimulated or maintained by estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19794821 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ARIMIDEX Approved UseAnastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. Launch Date8.2002241E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
39.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19470631 |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ANASTROZOLE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
648 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19470631 |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ANASTROZOLE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
yes [Ki 10 uM] | ||||
yes [Ki 10 uM] | ||||
yes [Ki 8 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
low | ||||
low | ||||
low | ||||
major | ||||
major | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Aromatase and aromatase inhibitors. | 2001 |
|
Third-generation aromatase inhibitors in the treatment of advanced breast cancer. | 2001 |
|
New combinations with Herceptin in metastatic breast cancer. | 2001 |
|
[Modern approaches to hormone therapy of breast cancer as a reflection of pathogenesis of the disease]. | 2001 |
|
Update on endocrine aspects of breast cancer: report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000. | 2001 |
|
[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies]. | 2001 Apr |
|
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. | 2001 Aug |
|
Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure. | 2001 Aug |
|
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. | 2001 Aug 3 |
|
Promising results for Arimidex and Femara. | 2001 Dec |
|
Future use of selective estrogen receptor modulators and aromatase inhibitors. | 2001 Dec |
|
The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients. | 2001 Dec |
|
Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? | 2001 Dec |
|
Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer. | 2001 Dec |
|
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. | 2001 Dec |
|
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. | 2001 Dec 1 |
|
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. | 2001 Jan-Mar |
|
Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer. | 2001 Jun |
|
Endocrine therapy in the treatment of metastatic breast cancer. | 2001 Jun |
|
The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. | 2001 Jun |
|
Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men. | 2001 Jun |
|
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer]. | 2001 May |
|
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. | 2001 May |
|
[Evolvement of hormone therapy for breast cancer. Florence, March 14, 2001]. | 2001 May-Jun |
|
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. | 2001 Nov 1 |
|
Role of anti-aromatase agents in postmenopausal advanced breast cancer. | 2001 Oct |
|
Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. | 2001 Oct 15 |
|
Aromatase inhibitors and inactivators in breast cancer. | 2001 Oct 20 |
|
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. | 2001 Sep |
|
Aromatase, aromatase inhibitors, and breast cancer. | 2001 Sep-Oct |
|
Estrogen as therapy for breast cancer. | 2002 |
|
Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer. | 2002 |
|
Gateways to Clinical Trials. | 2002 Apr |
|
Existing and emerging endocrine therapies for breast cancer. | 2002 Apr |
|
The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant. | 2002 Apr |
|
Antiaromatase agents: evolving role in adjuvant therapy. | 2002 Apr |
|
Effects of aromatase inhibition on in vitro follicle and oocyte development analyzed by early preantral mouse follicle culture. | 2002 Apr |
|
Aromatase inhibitors for male infertility. | 2002 Feb |
|
Hormones 'R' us. | 2002 Jan |
|
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact. | 2002 Jul 1 |
|
Letrozole for the management of breast cancer. | 2002 Jun |
|
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer. | 2002 Jun 22 |
|
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. | 2002 Mar |
|
Aromatase inhibitors in breast cancer. | 2002 Mar |
|
Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. | 2002 Mar-Apr |
|
Anti-aromatase agents in the treatment and prevention of breast cancer. | 2002 Mar-Apr |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25839436
Anastrozole, aromatase inhibitor was added at a concentration of 200 and 300 μg/mL to the endometrioma cells. The use of anastrozole significantly inhibited the growth of endometrioma cells, and estradiol secretion.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175563
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
WHO-VATC |
QL02BG03
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
WHO-ATC |
L02BG03
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
NCI_THESAURUS |
C2018
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
NDF-RT |
N0000175080
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
LIVERTOX |
56
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
120511-73-1
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
DB01217
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
7462
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
5137
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
2187
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
210
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
SUB05502MIG
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
120511-73-1
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
2Z07MYW1AZ
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
CHEMBL1399
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
1034807
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | USP-RS | ||
|
7274
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
84857
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | RxNorm | ||
|
M1889
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | Merck Index | ||
|
ANASTROZOLE
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
C1607
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
C090450
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)